The Becoming of Children With Doose Syndrome

Learning Disabilities Clinical Trial

— DOOSE  

Official title:

The Becoming of Children With Doose Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04048213
• Other study ID #: PI2018_843_0058
• Status: Recruiting
• Start date: August 1, 2019
• Est. completion date: December 2023

Study information

• Verified date: April 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Patrick Berquin, Pr
• Phone: (33)30322087670
• Email: berquin.patrick[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Doose syndrome is a rare epileptic syndrome that can lead to learning difficulties and a poor quality of life. The goal of this study is to evaluate the evolution of epilepsy and its consequences on cognitive development and learning issues in children with Doose syndrome.

Description:

Doose syndrome is a rare epileptic syndrome beginning between ages two and five, characterized by myoclonic-astatic seizures which can be associated with myoclonic seizures, astatic seizures, absences and generalized tonic-clonic seizures. These seizures can be difficult to treat effectively and may lead to learning difficulties. During this study, parents of children with Doose syndrome will receive a questionnaire regarding learning disabilities, quality of life and epilepsy of their children.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 6 Years

Eligibility

Inclusion Criteria:

• children with doose syndrome diagnosed between ages 1 and 6
• normal development until onset of seizures

Exclusion Criteria:

• unconfirmed diagnoses
• abnormal diagnoses
• abnormal psychomotor development before onset of seizures
• cerebral MRI abnormalities
• other child epileptic syndromes

Related Conditions & MeSH terms

• Doose Syndrome
• Epilepsies, Myoclonic
• Epilepsy
• Epileptic Syndromes
• Learning Disabilities
• Syndrome

Intervention

Other:
• questionnaire
questionnaire send to the parents

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (3)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens	University Hospital, Lille, University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease effects on the learning ability of children with doose syndrome	disease effects on the learning ability of children with doose syndrome base on scholar informations	day of inclusion
Secondary	Evolution of epilepsy in children with doose syndrome based on pathological symptoms	Evolution of epilepsy in children with doose syndrome based on pathological symptoms	day of inclusion